23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Editas Medicine, Inc. › 2025-2026

Editas Medicine, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Editas Medicine, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 237Asset managers, any item
  • 840Fund votes
  • June 17, 2026Meeting date

Results at a glance

Meeting of June 17, 2026: 4 items on Editas Medicine, Inc.’s Form 8-K, filed June 18, 2026: 2 approved · 2 passed (calculated).

Dissent

Significant dissent: 1 director (27.4% against).

Notable dissent: 1 other board item (16.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13F, 5.8%, as of September 30, 2026)

Explore Editas Medicine, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Editas Medicine, Inc.

These tallies are Editas Medicine, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Editas Medicine, Inc. — official shareholder meeting results, meeting held June 17, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Bernadette Connaughton 28,660,181---- 10,789,54926,404,190 73%Passed (calculated)—
Elect Director: Elliott Levy, M.D. 37,095,058---- 2,354,67226,404,190 94%Passed (calculated)—
2. The compensation paid to its named executive officers 32,914,2586,322,885212,587 --26,404,190 84%Approved—
3. The selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 64,686,839774,471392,610 --0 99%Approved—

Source: Editas Medicine, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.

How asset managers voted at the Editas Medicine, Inc. 2025-2026 meeting

237 asset managers disclosed a vote on at least one Editas Medicine, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Bernadette Connaughton

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%WITHHELD
FOR: 28,660,181WITHHELD: 10,789,549
Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Bernadette Connaughton

Editas Medicine, Inc.’s own tally for this item (“Elect Director: Bernadette Connaughton”): 28,660,181 for, 10,789,549 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 13,679,209 for, 1,173,183 withheld, 1,827,587 abstained.

FOR
FOR: 13,679,209ABSTAIN: 1,827,587WITHHOLD: 1,173,183
Largest asset managers voting on “Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Bernadette Con” at Editas Medicine, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,313,0830 6113,693For
Fidelity2,140,5980 042,900For
BlackRock306,6020 1,653,4310Mixed
TIAA1,903,3180 00For
Charles Schwab862,5650 00For
JPMorgan588,5400 00For
Equitable00 0259,336Withhold
Lincoln Financial127,6770 00For
BRIDGEWAY FUNDS INC00 0126,000Withhold
AIG/SunAmerica00 0119,137Withhold
Brighthouse77,2820 032,151Mixed
SEI108,9860 00For
QUANTITATIVE MASTER SERIES LLC00 108,8850Abstain
Columbia Threadneedle00 095,483Withhold
Global X92,2730 00For
Nationwide3,3410 086,738Withhold
Voya00 057,070Withhold
Northern Trust00 055,991Withhold
T. Rowe Price00 055,067Withhold
AQR00 041,896Withhold
Pacific Life00 040,292Withhold
Bridge Builder Trust00 39,8500Abstain
Goldman Sachs00 037,079Withhold
Russell Investments36,6570 00For
Invesco35,5700 00For

Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).

Elect Director: Elliott Levy, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 37,095,058WITHHELD: 2,354,672
Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Elliott Levy, M.D.

Editas Medicine, Inc.’s own tally for this item (“Elect Director: Elliott Levy, M.D.”): 37,095,058 for, 2,354,672 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 16,510,339 for, 169,635 withheld, 5 abstained.

FOR
FOR: 16,510,339ABSTAIN: 5WITHHOLD: 169,635
Largest asset managers voting on “Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Elliott Levy, ” at Editas Medicine, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,326,8320 50For
Fidelity2,183,4980 00For
BlackRock1,960,0330 00For
TIAA1,903,3180 00For
Charles Schwab862,5650 00For
JPMorgan588,5400 00For
Equitable154,7260 0104,610Mixed
Lincoln Financial127,6770 00For
BRIDGEWAY FUNDS INC126,0000 00For
AIG/SunAmerica119,1370 00For
Brighthouse109,4330 00For
SEI108,9860 00For
QUANTITATIVE MASTER SERIES LLC108,8850 00For
Columbia Threadneedle95,4830 00For
Global X92,2730 00For
Nationwide90,0790 00For
Voya57,0700 00For
Northern Trust00 055,991Withhold
T. Rowe Price55,0670 00For
AQR41,8960 00For
Pacific Life40,2920 00For
Bridge Builder Trust39,8500 00For
Goldman Sachs37,0790 00For
Russell Investments36,6570 00For
Invesco35,5700 00For

Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).

The compensation paid to its named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

84% Approved · of votes cast

FOR 84%AGAINST
FOR: 32,914,258AGAINST: 6,322,885

Prior year: 61.1% for (May 29, 2025 meeting) ▲ 22.8 pts

Details: description as filed, official tally, votes by 237 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Editas Medicine, Inc.’s own tally for this item (“2. The compensation paid to its named executive officers”): 32,914,258 for, 6,322,885 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation paid to its named executive officers.”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 47 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Editas Medicine, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,326,80233 10For
Fidelity2,140,59842,900 00For
BlackRock1,960,0330 00For
TIAA1,903,3180 00For
Charles Schwab862,5650 00For
JPMorgan588,5400 00For
Equitable154,726104,610 00Mixed
Lincoln Financial127,6770 00For
BRIDGEWAY FUNDS INC0126,000 00Against
AIG/SunAmerica0119,137 00Against
Brighthouse77,28232,151 00Mixed
SEI108,9860 00For
QUANTITATIVE MASTER SERIES LLC108,8850 00For
Columbia Threadneedle095,483 00Against
Global X92,2730 00For
Nationwide28,59461,485 00Mixed
Investment Managers Series Trust II064,082 00Against
Voya57,0700 00For
Northern Trust055,991 00Against
T. Rowe Price055,067 00Against
AQR041,896 00Against
Pacific Life40,2920 00For
Bridge Builder Trust39,8500 00For
Goldman Sachs37,0790 00For
Russell Investments36,6570 00For

Fund voting reports, all 47 managers: 15,782,424 for, 952,656 against, 9,035 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 202 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Editas Medicine, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock3,578,8701,571 00For
GEODE CAPITAL MANAGEMENT, LLC2,451,9630 00For
Nuveen1,977,5090 00For
State Street1,476,8188,045 00For
ACADIAN ASSET MANAGEMENT LLC01,108,735 00Against
KENNEDY CAPITAL MANAGEMENT LLC0871,149 00Against
Charles Schwab862,7510 00For
Vanguard657,05534,006 00For
MACKENZIE FINANCIAL CORP664,6620 00For
Northern Trust0533,895 00Against
DE Shaw0407,973 00Against
TRUST CO OF OKLAHOMA392,5500 00For
AQR0350,384 00Against
Goldman Sachs275,0040 00For
MELLON INVESTMENTS Corp247,0910 00For
T. Rowe Price0205,440 00Against
AllianceBernstein0167,530 00Against
JACOBS LEVY EQUITY MANAGEMENT, INC0151,743 00Against
Green Alpha Advisors, LLC0127,495 00Against
BRIDGEWAY CAPITAL MANAGEMENT, LLC0126,000 00Against
JPMorgan121,4560 00For
Allianz0118,050 00Against
SEI109,3460 00For
Fidelity100,1330 00For
STIFEL NICOLAUS & CO INC \MO\098,211 00Against

Institutional-manager reports, all 202 managers: 13,489,880 for, 4,946,039 against, 2,770 abstained, 18,381 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 64,686,839AGAINST: 774,471

Prior year: 97.8% for (May 29, 2025 meeting) ▲ 1.0 pts

Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Editas Medicine, Inc.’s own tally for this item (“3. The selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 64,686,839 for, 774,471 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 16,735,025 for, 1 against, 9,035 abstained.

FOR
FOR: 16,735,025AGAINST: 1ABSTAIN: 9,035
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public account” at Editas Medicine, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard7,326,8351 10For
Fidelity2,183,4980 00For
BlackRock1,960,0330 00For
TIAA1,903,3180 00For
Charles Schwab862,5650 00For
JPMorgan588,5400 00For
Equitable259,3360 00For
Lincoln Financial127,6770 00For
BRIDGEWAY FUNDS INC126,0000 00For
AIG/SunAmerica119,1370 00For
Brighthouse109,4330 00For
SEI108,9860 00For
QUANTITATIVE MASTER SERIES LLC108,8850 00For
Columbia Threadneedle95,4830 00For
Global X92,2730 00For
Nationwide90,0790 00For
Investment Managers Series Trust II64,0820 00For
Voya57,0700 00For
Northern Trust55,9910 00For
T. Rowe Price55,0670 00For
AQR41,8960 00For
Pacific Life40,2920 00For
Bridge Builder Trust39,8500 00For
Goldman Sachs37,0790 00For
Russell Investments36,6570 00For

Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).

Largest Editas Medicine, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 97,866,996 shares outstanding at the time of that meeting.

Fund voting reports: top Editas Medicine, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 7.49%
2Fidelity 2.23%
3BlackRock 2.00%
4TIAA 1.94%
5Charles Schwab 0.88%
6JPMorgan 0.60%
7Equitable 0.26%
8Lincoln Financial 0.13%
9BRIDGEWAY FUNDS INC 0.13%
10AIG/SunAmerica 0.12%
Institutional-manager reports: top Editas Medicine, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE…”, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 3.66%
2GEODE CAPITAL MANAGEMENT, LLC 2.51%
3Nuveen 2.02%
4State Street 1.52%
5ACADIAN ASSET MANAGEMENT LLC 1.13%
6KENNEDY CAPITAL MANAGEMENT LLC 0.89%
7Charles Schwab 0.88%
8Vanguard 0.71%
9MACKENZIE FINANCIAL CORP 0.68%
10Northern Trust 0.55%

Reported Editas Medicine, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Editas Medicine, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Commodore Capital LP16,045,802 16.40%Schedule 13G, filed June 2, 2026
TCG Crossover GP III, LLC15,798,999 16.14%Schedule 13G, filed June 3, 2026
BlackRock9,263,312 9.47%Form 13F, quarter ended March 31, 2026
RA Capital Management, L.P.8,889,000 9.08%Schedule 13G, filed June 3, 2026
Vanguard Group8,208,068 8.39%Form 13F, quarter ended March 31, 2026
Renaissance Technologies3,972,160 4.06%Form 13F, quarter ended March 31, 2026
Geode Capital2,311,789 2.36%Form 13F, quarter ended March 31, 2026
State Street2,076,122 2.12%Form 13F, quarter ended March 31, 2026
JPMorgan Chase1,947,384 1.99%Form 13F, quarter ended March 31, 2026
D.E. Shaw1,943,893 1.99%Form 13F, quarter ended March 31, 2026

Percentages above are of 97,866,996 shares outstanding, as reported by Editas Medicine, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Editas Medicine, Inc.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 237 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 840 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE… — Editas Medicine, Inc.'s filing reports the proposal as approved, with 84% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Editas Medicine, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Editas Medicine, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Editas Medicine, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Editas Medicine (EDIT) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/editas-medicine-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.